Laddar...
Siponimod: A Review in Secondary Progressive Multiple Sclerosis
Oral siponimod (Mayzent(®)), a next-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary progressive multiple sclerosis (SPMS), with specific indications varying between individual countries. In the pivotal E...
Sparad:
| I publikationen: | CNS Drugs |
|---|---|
| Huvudupphovsman: | |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Springer International Publishing
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7773609/ https://ncbi.nlm.nih.gov/pubmed/33108633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-020-00771-z |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|